{
    "organizations": [],
    "uuid": "134ec11bd5c574c4a5a1f20e81177b76e4753c62",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/09/globe-newswire-vbl-therapeutics-to-report-fiscal-2017-results-on-march-15.html",
    "ord_in_thread": 0,
    "title": "VBL Therapeutics to Report Fiscal 2017 Results on March 15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, March 15 at 8:30am Eastern Time to report fiscal year ended December 31, 2017 financial results.\nThursday, March 15th @ 8:30am Eastern Time Domestic: 877-222-6394 International: 703-925-2702 Conference ID: 7392936 Webcast: https://edge.media-server.com/m6/p/y3srj89d Replays, Available through March 29th: Domestic: 855-859-2056 International: 404-537-3406 Conference ID: 7392936 About VBL\nVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.\nINVESTOR CONTACT:\nMichael Rice\nLifeSci Advisors, LLC\n(646) 597-6979\nMEDIA CONTACT:\nMatt Middleman, M.D.\nLifeSci Public Relations\nmatt@lifescipublicrelations.com\n(646) 627-8384\nSource: VBL Therapeutics",
    "published": "2018-03-09T16:00:00.000+02:00",
    "crawled": "2018-03-09T15:46:00.062+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "tel",
        "aviv",
        "israel",
        "march",
        "globe",
        "newswire",
        "vbl",
        "therapeutic",
        "nasdaq",
        "vblt",
        "biotechnology",
        "company",
        "focused",
        "discovery",
        "development",
        "commercialization",
        "treatment",
        "cancer",
        "today",
        "announced",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "march",
        "eastern",
        "time",
        "report",
        "fiscal",
        "year",
        "ended",
        "december",
        "financial",
        "result",
        "thursday",
        "march",
        "15th",
        "eastern",
        "time",
        "domestic",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "replay",
        "available",
        "march",
        "29th",
        "domestic",
        "international",
        "conference",
        "id",
        "vbl",
        "vascular",
        "biogenics",
        "operating",
        "vbl",
        "therapeutic",
        "clinical",
        "stage",
        "biopharmaceutical",
        "company",
        "focused",
        "discovery",
        "development",
        "commercialization",
        "treatment",
        "cancer",
        "company",
        "lead",
        "oncology",
        "product",
        "candidate",
        "ofranergene",
        "obadenovec",
        "targeted",
        "agent",
        "positioned",
        "treat",
        "wide",
        "range",
        "solid",
        "tumor",
        "conveniently",
        "administered",
        "iv",
        "infusion",
        "every",
        "two",
        "month",
        "observed",
        "cancer",
        "patient",
        "demonstrated",
        "efficacy",
        "signal",
        "comer",
        "phase",
        "trial",
        "well",
        "three",
        "phase",
        "study",
        "ofranergene",
        "obadenovec",
        "currently",
        "studied",
        "phase",
        "trial",
        "ovarian",
        "cancer",
        "investor",
        "contact",
        "michael",
        "rice",
        "lifesci",
        "advisor",
        "llc",
        "medium",
        "contact",
        "matt",
        "middleman",
        "lifesci",
        "public",
        "relation",
        "matt",
        "source",
        "vbl",
        "therapeutic"
    ]
}